于波中國(guó)醫(yī)大一院-資料下載頁(yè)
2025-07-18 06:36本頁(yè)面
【正文】 ry to describe the clinical epidemiology of AF ablation, and the diagnostic/therapeutic processes applied in Europe ? Arrhythmia documentation was done by an ECG in 76%, Holter in 52%, transtelephonic monitoring in 8%, and/or implanted systems in % Eur Heart J June 21, 2022 35 (24) First published online: January 31, 2022 72 centres in 10 countries to enrol 20pts doing a 1st PVI Oct, 2022 May, 2022 1391 pts PVI(%),1300 pts (%) pleted followup 367 177。 42 days Rate of use of pharmacological treatment at discharge and at the 12month ?49% of pts under AAD at 12month ?Paroxysmal AF more off drugs (55%) pared with nonparoxysmal AF (%) (P = ) ?Pts referring symptoms during the followup more likely to be under AAD ( vs %, P ) Eur Heart J June 21, 2022 35 (24) First published online: January 31, 2022 The aims： 1year followup to analyse how centres assess in routine clinical practice the success of the procedure and longterm safety Flowchart representing numbers of individuals at each stage of the study ?arrhythmia recurrences during the blanking period were also inversely associated with the 1year success (P = ) ?Success w/t AAD in 522 pts (%) (% in paroxysmal AF。 % in persistent AF。 % in longlasting persistent AF) Eur Heart J June 21, 2022 35 (24) First published online: January 31, 2022 1year success in 1281 pts 1 episode of atrial arrhythmias in 459pts (%) 194 pts (%) 1 episode of atrial arrhythmia 334 (%) had 1 recurrence Kaplan– Meier arrhythmiafree survival curve by type of atrial fibrillation Eur Heart J June 21, 2022 35 (24) First published online: January 31, 2022 ?50%pts asymptomatic after the PVI ?26% of recurrences were asymptomatic ?After PVI, maintain sinus rhythm in % in the absence of AAD, and in an additional % with the use of AAD formerly ineffective % % ?短期應(yīng)用 AAD可以減少房顫消融術(shù)后早期復(fù)發(fā)，但不能防止晚期復(fù)發(fā) ? AAD應(yīng)該只在房顫消融后短期內(nèi)（ 3個(gè)月）應(yīng)用，大多數(shù)患者不應(yīng)該長(zhǎng)期應(yīng)用 ?房顫消融后 AAD廣泛使用可能反映了一些醫(yī)生對(duì)消融療效缺乏信心而不是病人真正需要 AAD治療 ?應(yīng)該記住使用 AAD可能產(chǎn)生潛在增加發(fā)病率和死亡率風(fēng)險(xiǎn) ?AAD對(duì)常發(fā)生在消融后空白期內(nèi)的大折返性心動(dòng)過(guò)速功效需進(jìn)一步證明 ?目前為止理論上所謂上游治療可能使房顫消融后心房重構(gòu)逆轉(zhuǎn)的結(jié)論仍未證實(shí) Expert Rev CardiovascTher. 2022。11(7):837842. 房顫導(dǎo)管消融術(shù)后抗心律失常藥物的應(yīng)用：時(shí)機(jī)與建議
語(yǔ)文相關(guān)推薦
鄂ICP備17016276號(hào)-1